{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00861:a retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00861%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.004527,
    "timestamp_received": "2026-04-25T14:13:29.889512+00:00Z",
    "timestamp_returned": "2026-04-25T14:13:29.894039+00:00Z",
    "trace_id": "1a53914b-fdf0-4bc9-b64b-ebd3c00f46fb"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:hse.00861:a",
      "indication": "Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.",
      "initial_approval_date": "2024-06-01",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with chemotherapy for reimbursement as a treatment option for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence. This cited regimen is specifically for pembrolizumab 400mg in combination with weekly carboplatin AUC 1.5 and paclitaxel 80mg/m^2 followed by dose dense doxorubicin and cyclophosphamide (AC 60/600) therapy.",
      "raw_biomarkers": null,
      "raw_cancer_type": "locally advanced or early stage triple-negative breast cancer",
      "raw_therapeutics": "Pembrolizumab in combination with chemotherapy (carboplatin and paclitaxel followed by doxorubicin and cyclophosphamide)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00861",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2025, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6453/861_v2_Pembro_Carbo_AUC_1.5_Pacli_80_DDAC.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6453/861_v2_Pembro_Carbo_AUC_1.5_Pacli_80_DDAC.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2024-07-18",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}